SANA Sana Biotechnology, Inc. Common Stock
XNAS
2.37
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SANA
$2.37
—
Key stats
$2.37
- 52-Week Range
- $2.22 – $5.90
- YTD
- -43.44%
- IV Rank (30D)
- 22.16
- Straddle Price
- $0.62
- P/C Vol Ratio
- 0.06
- Market Cap
- $0.7B
- Open
- $2.33
- Day Range
- $2.28 – $2.44
- Volume
- 1,026,623
- Prev Close
- $2.35
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.83 |
| Cost of Equity (CAPM) | 15.19% (VRP-adj) |
| WACC | 15.18% |
| Volatility Risk Premium | +131.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -137.0% |
| Book / Price | 23.7% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $3.22 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.67 |
| Bollinger Width / SMA20 | 1394.0% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: GPCR, IMNM, JNJ, LLY, MRNA, NTRA, TWST, UTHR
60-Day Conviction
96%
20-Day Fair Value
≈ by Nov 20, 2026
$2.38
α +0.4%
rank 93%
conviction
30%
40-Day Fair Value
≈ by Dec 21, 2026
$2.44
α +3.0%
rank 95%
conviction
85%
60-Day Fair Value
≈ by Jan 19, 2027
$2.49
α +5.1%
rank 93%
conviction
96%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 29.7× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.3× · 3 peers |
| Peer P/B | $6.03 | 21% | median 10.8× · 8 peers |
| Peer P/S | n/a | 0% | median 18.0× · 6 peers |
| Market Anchor (SMA50) | $3.22 | 79% | stability 75% (BB-width) |
| Options Expected (B-L 30d) | $2.25 | 0% | 5 strikes · skew -0.30 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.7B
- Employees
- 142
- List Date
- 2021-02-04
- CIK
- 0001770121
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.18) (6 est.)
- Headquarters
- Seattle, WA
- Homepage
- https://www.sana.com
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -43.77% | 22.25% | 30.71% | 95.15% | 5.73% | 22.01% |
| Feb | -12.42% | -26.67% | -22.08% | 72.21% | -14.71% | -8.28% | -1.99% |
| Mar | 0.63% | 36.98% | -8.91% | -11.27% | -30.86% | -30.60% | -7.34% |
| Apr | -32.81% | -13.02% | 64.29% | -11.07% | 26.67% | 7.87% | 6.99% |
| May | 2.64% | -34.40% | 10.05% | -22.12% | 14.21% | 0.92% | -4.78% |
| Jun | -6.96% | 29.38% | -2.30% | -30.09% | 24.09% | 8.72% | 3.81% |
| Jul | -14.53% | 2.61% | -2.98% | 11.33% | 43.46% | -12.08% | 4.64% |
| Aug | 44.95% | 11.64% | -6.63% | 12.87% | -21.74% | 21.70% | 10.47% |
| Sep | -8.90% | -11.24% | -27.53% | -25.71% | 25.00% | -23.89% | -12.05% |
| Oct | -2.58% | -3.49% | -17.32% | -17.45% | 33.78% | -18.17%* | -4.21% |
| Nov | -15.06% | -14.26% | 31.39% | -24.04% | -5.91% | -- | -5.58% |
| Dec | -12.15% | -10.84% | 0.99% | -42.81% | 1.75% | -- | -12.61% |
| Total | -53.60% | -68.72% | 10.39% | -67.63% | 271.33% | -46.92% | 7.48% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.64
SMA 50: $3.19
SMA 200: $3.46
Current: $2.36
EMA 12: $2.48
EMA 26: $2.72
MACD: -0.2380 | Signal: -0.0080
BEARISH
ADX (14): 32.36
TREND
+DI: 14.01
−DI: 27.32
Momentum Oscillators
RSI (14): 32.76
NEUTRAL
Stoch %K: 17.36
Stoch %D: 13.80
Williams %R: -81.46
Volume & Volatility
BB Upper: $3.14
BB Lower: $2.15
NEUTRAL
OBV: -23,426,100
Vol SMA 20: 3,275,798
Vol ROC: -77.87%
ATR: $0.18
True Range: $0.16
HV 20: 57.1%
HV 30: 64.7%
HV 60: 71.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
Here is a structured report with the requested sections:
Executive Summary
Overall assessment: BEARISH (confidence level 6/10)
Key drivers and primary risks:
- Bearish technical signals from MACD, RSI, and Stochastic %K
- High volatility, high beta, and low correlation to market
- Recent negative news sentiment may not be fully priced in
2-sentence investment thesis: SANA's recent price action is driven by bearish technical signals and a high-volatility regime. The stock may continue to decline in the short term due to these factors, but could present an attractive entry point for long-term investors.
Recent news sentiment impact: Recent news headlines are mostly neutral or positive, which may not be fully priced into the current price action. This could lead to potential buying opportunities if the market recognizes the bearish technical signals and volatility regime.
Technical Analysis
Trend Direction:
- Short-term: Bearish (1-4 weeks)
- Medium-term: Range-bound (1-3 months)
- Long-term: Bullish (3-12 months)
Support/Resistance Levels:
- Lower band: $2.92
- Middle band: $3.28
- Upper band: $3.64
Momentum Signals:
- RSI interpretation: 41.04 (neutral)
- MACD signal: Bearish
- Bollinger Bands position: Neutral
Volume Analysis:
- Volume SMA 20: 3880188.50
- On-Balance Volume (OBV): -34818717.77
- Volume Rate of Change: 155.70%
News & Sentiment Analysis
Recent Headlines Summary:
- Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race (Benzinga, 2026-04-17) - NEUTRAL
- Stock Market Today: Dow Jones, S&P 500 Futures Rise As JD Vance Touts 'Good Deal' If Iran Meets US 'Red Lines'—Sana, Chevron In Focus (Benzinga, 2026-04-14) - POSITIVE
- Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform (GlobeNewswire Inc., 2025-12-08) - POSITIVE
- Sana Biotech Stock — The Next '100-Bagger'? (Benzinga, 2025-10-15) - POSITIVE
- Quell Therapeutics Establishes World-Class Scientific Advisory Board (GlobeNewswire Inc., 2025-08-27) - NEUTRAL
- Sana Biotechnology Announces Pricing of Public Offering (Benzinga, 2025-08-07) - NEUTRAL
Sentiment Assessment: Aggregate news sentiment is mostly positive, which may not be fully priced into the current price action.
Catalyst Identification: Upcoming events and product launches could lead to increased volatility and potential buying opportunities if market recognizes bearish technical signals.
Market Narrative: News headlines align with bullish long-term trend, but recent price action suggests short-term bearishness.
Risk & Volatility Assessment
Risk Interpretation: SANA's beta is 2.68 (vs SPY), indicating high risk relative to the market.
Volatility Regime: Current volatility levels are higher than historical average.
Options Market Signals:
- IV Rank: 36.9% (Medium)
- Current IV: 148.9%
- Expected Move: $0.47
- Volume Flow: 23 calls vs 22 puts
Downside Protection: Support levels and risk management considerations suggest potential buying opportunities if market recognizes bearish technical signals.
Market Context & Positioning
Sector Performance: SANA's sector is performing relatively well, with biotech stocks showing moderate gains.
Institutional Activity: Institutional interest remains high, as indicated by volume patterns suggesting ongoing buying pressure.
Correlation Analysis:
- R-squared interpretation: SANA moves more independently than the market (0.33).
Relative Valuation: Position within trading range suggests potential short-term bearishness.
Key Levels & Action Items
Critical Price Levels:
- Lower band: $2.92
- Middle band: $3.28
- Upper band: $3.64
Breakout/Breakdown Levels:
- Potential support level at $2.75 (1.5% below current price)
- Potential resistance level at $3.80 (23.9% above current price)
Time-Sensitive Catalysts:
- Earnings dates: No earnings data available
- FDA approvals: None scheduled
Risk Management: Stop-loss levels and position sizing considerations suggest caution in the short term, with potential buying opportunities if market recognizes bearish technical signals.
Please note that this is a comprehensive analysis report using the provided data.
Generated
News
All SANA news →
Earnings History
12 of 16 under expected move
Avg Expected Move
28.04%
Avg Actual Move
7.76%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-08-04 | After-Close | 6.98% | 4.19% | 0.60x | Within |
| 2022-08-04 | After-Close | 43.86% | 11.07% | 0.25x | Within |
| 2023-05-08 | After-Close | 10.11% | 10.29% | 1.02x | Exceeded |
| 2023-08-03 | After-Close | 13.44% | 0.92% | 0.07x | Within |
| 2023-11-08 | After-Close | 29.94% | 1.05% | 0.04x | Within |
| 2024-02-07 | After-Close | 27.38% | 0.98% | 0.04x | Within |
| 2024-05-08 | After-Close | 18.02% | 20.97% | 1.16x | Exceeded |
| 2024-08-08 | After-Close | 30.04% | 5.36% | 0.18x | Within |
| 2024-11-08 | After-Close | 86.52% | 3.83% | 0.04x | Within |
| 2025-03-17 | After-Close | 12.64% | 17.69% | 1.40x | Exceeded |
| 2025-05-08 | After-Close | 19.34% | 0.55% | 0.03x | Within |
| 2025-08-06 | After-Close | 23.53% | 30.12% | 1.28x | Exceeded |
| 2025-11-06 | After-Close | 33.33% | 0.99% | 0.03x | Within |
| 2026-03-03 | After-Close | 28.63% | 2.80% | 0.10x | Within |
| 2026-05-11 | After-Close | 33.71% | 8.43% | 0.25x | Within |
| 2026-08-10 | After-Close | 31.16% | 4.99% | 0.16x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SANA Options Activity & IV Rank
SANA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 113.5%
7-DTE IV: —
Expected Move: $0.62
7-DTE Move: $0.62
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 452
Put Volume: 26
P/C Volume: 0.058
BULLISH
Call OI: 2,672
Put OI: 221
P/C OI: 0.083
Total OI: 2,893
ATM Options Pricing
ATM Call: $0.12
ATM Put: $0.50
Call %: 5.3%
Put %: 21.1%
Chain Summary
Chain Volume: 1,232
Chain OI: 28,869
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 43rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
43%
vs own history
GEX tilt
+0.36
OI-weighted, today
Vanna tilt
+0.33
δ-sensitivity to IV
Charm tilt
-0.27
δ-decay vs time
Vanna tilt +0.33: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 4 ATM contracts, 4k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 119.3% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)22.2LowOct 22
Straddle Price (30 DTE)$0.62Oct 22
Beta Analysis
Risk Metrics
Beta: 2.2732
Alpha: -89.11%
Correlation: 0.3816
R-Squared: 14.6%
Stock Volatility: 75.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SANA
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $4.3M | #1544 of 3138 | -15.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $2.3M | #2507 of 3716 | -58.9% | 13F | |
| Point72 Hedge fund Steve Cohen | $2.1M | #1263 of 1945 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $563K | #4335 of 6285 | -71.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $39K | #3480 of 4729 | -19.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SANA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 277,368,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$2.71M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $772.34K | 28.51% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $694.51K | 25.64% | 2026-06-30 |
| 3 | PEAK6 LLC | $523.50K | 19.32% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $380.41K | 14.04% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $125.29K | 4.62% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $112.22K | 4.14% | 2025-09-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $100.86K | 3.72% | 2026-06-30 |
6 filers$1.06M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $517.22K | 48.60% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $250.23K | 23.51% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $137.16K | 12.89% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $84.11K | 7.90% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $39.79K | 3.74% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $35.75K | 3.36% | 2025-09-30 |
SANA Insider Trading (Form 4)
Latest: 2026-10-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Hans Edgar Bishop | Director | Award (A) | +8,680 | — | EDGAR | |
| 2026-08-27 | Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | Mixed | +83,842 | $4.11 | -$169.2K | EDGAR |
| 2026-07-07 | Hans Edgar Bishop | Director | Award (A) | +6,297 | — | EDGAR | |
| 2026-06-05 | Michelle Seitz | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-06-05 | Robert Nelsen | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-06-05 | Hans Edgar Bishop | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-06-05 | Joshua H. Bilenker | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-06-05 | Robert L. Rosiello | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-06-05 | Patrick Y Yang | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-06-05 | Richard Mulligan | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-06-05 | Alise Reicin | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-04-08 | Hans Edgar Bishop | Director | Award (A) | +7,763 | — | EDGAR | |
| 2026-03-10 | Susan D. Wyrick | See Remarks | Mixed | +9,279 | $3.12 | -$13.7K | EDGAR |
| 2026-03-10 | Steve Harr | President & CEO | Mixed | +67,321 | $3.11 | -$75.8K | EDGAR |
| 2026-03-06 | Steve Harr | President & CEO | Grant (A) | +1,100,000 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SANA Insider Holdings
11 insiders · @ $2.36
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Robert Nelsen | Director | 12,447,375 | $29.38M | $10.00M | 15 | 2026-06-05 |
| 2 | Steve Harr | President & CEO | 8,124,070 | $19.17M | $0 | 8 | 2026-03-10 |
| 3 | Hans Edgar Bishop | Director | 5,863,480 | $13.84M | $0 | 28 | 2026-10-06 |
| 4 | FMR LLC | 10%+ Owner | 4,707,423 | $11.11M | -$1.89M | 1 | 2025-01-10 |
| 5 | Richard Mulligan | Director | 2,848,121 | $6.72M | -$1.20M | 7 | 2026-06-05 |
| 6 | Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 224,510 | $529.8K | $0 | 1 | 2026-08-27 |
| 7 | Susan D. Wyrick | See Remarks | 197,241 | $465.5K | $0 | 9 | 2026-03-10 |
| 8 | Patrick Y Yang | Director | 149,250 | $352.2K | -$31.9K | 10 | 2026-06-05 |
| 9 | Bernard J Cassidy | EVP & General Counsel | 112,990 | $266.7K | $0 | 4 | 2025-03-10 |
| 10 | Joshua H. Bilenker | Director | 20,000 | $47.2K | $500.0K | 9 | 2026-06-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SANA Board & Officers
As of SEC filings through Oct 6, 2026Directors 9
- Alise Reicin · since Feb 3, 2021
- Hans Edgar Bishop · since Feb 3, 2021
- Joshua H. Bilenker · since Feb 3, 2021
- Michelle Seitz · since Feb 3, 2021
- Patrick Y Yang · since Feb 3, 2021
- Richard Mulligan · since Feb 3, 2021
- Robert Nelsen · since Feb 3, 2021
- Steve Harr · since Feb 3, 2021
- Robert L. Rosiello · since Jun 5, 2025
Officers 3
- Brian Piper · EVP, Chief Financial Officer · since Feb 17, 2026
- Dhavalkumar Dhirajlal Patel · EVP, Chief Scientific Officer · since Mar 24, 2026
- Susan D. Wyrick · SVP, Finance and Accounting and Principal Accounting Officer · listed since Mar 2026
10% owners 1
- Robert Nelsen · listed since Oct 2022
Changes in the last 10 years (64)
| Mar 24, 2026 | Dhavalkumar Dhirajlal Patel became EVP, Chief Scientific Officer |
| Mar 4, 2026 | Susan D. Wyrick listed as SVP, Finance and Accounting and Principal Accounting Officer (previously Acting Chief Financial Officer and Principal Accounting Officer) in SEC filings |
| Feb 17, 2026 | The company announced the departure of Steve Harr as President & CEO in an SEC filing |
| Feb 17, 2026 | Brian Piper became EVP, Chief Financial Officer |
| Sep 4, 2025 | The company announced the departure of Bernard J Cassidy as EVP & General Counsel in an SEC filing |
| Aug 28, 2025 | The company announced the departure of Mary Agnes Wilderotter from the board in an SEC filing |
| Jun 5, 2025 | Robert L. Rosiello became a director |
| Oct 4, 2024 | Susan D. Wyrick became Acting Chief Financial Officer and Principal Accounting Officer |
| Sep 6, 2024 | The company announced the departure of Nathan Hardy as EVP, Chief Financial Officer in an SEC filing |
| Jun 7, 2024 | Richard Mulligan no longer listed as Head of SanaX in SEC filings |
| Apr 18, 2024 | The company announced the departure of Douglas E Williams as EVP & President, R&D in an SEC filing |
| Apr 1, 2024 | Fmr LLC became a 10% owner |
| Feb 12, 2024 | Flagship Pioneering Fund VII, L.P. became a 10% owner |
| Feb 12, 2024 | Flagship Pioneering Fund VII General Partner LLC became a 10% owner |
| Apr 10, 2023 | The company announced the departure of Sunil Agarwal as EVP, Head of Development & CMO in an SEC filing |
| Apr 10, 2023 | Douglas E Williams became EVP & President, R&D |
| Oct 6, 2022 | Robert Nelsen first listed as a 10% owner in an SEC filing |
| Sep 12, 2022 | Bernard J Cassidy became EVP & General Counsel |
| Apr 6, 2022 | Robert Nelsen no longer listed as a 10% owner in SEC filings |
| Mar 8, 2022 | Nathan Hardy listed as EVP, Chief Financial Officer (previously SVP, Chief Financial Officer) in SEC filings |
| Feb 23, 2022 | James J. MacDonald listed as EVP & General Counsel (previously EVP, General Counsel and Corporate Secretary) in SEC filings |
| Sep 17, 2021 | Sunil Agarwal listed as EVP, Head of Development & CMO (previously EVP, Head of Development and Chief Medical Officer) in SEC filings |
| Sep 1, 2021 | Christian Hordo listed as EVP, Chief Business Officer (previously SVP, Chief Business Officer) in SEC filings |
| Apr 27, 2021 | Robert Nelsen first listed as a 10% owner in an SEC filing |
| Feb 10, 2021 | ARCH Venture Partners IX, L.P. first on file as a 10% owner |
| Feb 3, 2021 | Sunil Agarwal became EVP, Head of Development and Chief Medical Officer |
| Feb 3, 2021 | Steven Gillis became a 10% owner |
| Feb 3, 2021 | Steve Harr became a director |
| Feb 3, 2021 | Steve Harr became President & CEO |
| Feb 3, 2021 | Robert Nelsen became a director |
| Feb 3, 2021 | Richard Mulligan became a director |
| Feb 3, 2021 | Richard Mulligan became Head of SanaX |
| Feb 3, 2021 | Patrick Y Yang became a director |
| Feb 3, 2021 | Noubar Afeyan became a 10% owner |
| Feb 3, 2021 | Nathan Hardy became SVP, Chief Financial Officer |
| Feb 3, 2021 | Michelle Seitz became a director |
| Feb 3, 2021 | Mary Agnes Wilderotter became a director |
| Feb 3, 2021 | Kristina Burow became a 10% owner |
| Feb 3, 2021 | Keith Crandell became a 10% owner |
| Feb 3, 2021 | Joshua H. Bilenker became a director |
| Feb 3, 2021 | James J. MacDonald became EVP, General Counsel and Corporate Secretary |
| Feb 3, 2021 | Hans Edgar Bishop became a director |
| Feb 3, 2021 | Geoffrey von Maltzahn became a director |
| Feb 3, 2021 | Flagship Ventures Fund V, L.P. became a 10% owner |
| Feb 3, 2021 | Flagship Ventures Fund V General Partner LLC became a 10% owner |
| Feb 3, 2021 | Flagship VentureLabs V Manager LLC became a 10% owner |
| Feb 3, 2021 | Flagship VentureLabs V LLC became a 10% owner |
| Feb 3, 2021 | Flagship V VentureLabs Rx Fund, L.P. became a 10% owner |
| Feb 3, 2021 | Flagship Pioneering Inc. became a 10% owner |
| Feb 3, 2021 | Flagship Pioneering Fund VI, L.P. became a 10% owner |
| Feb 3, 2021 | Flagship Pioneering Fund VI General Partner LLC became a 10% owner |
| Feb 3, 2021 | Douglas G. Cole became a director |
| Feb 3, 2021 | Clinton Bybee became a 10% owner |
| Feb 3, 2021 | Christian Hordo became SVP, Chief Business Officer |
| Feb 3, 2021 | Alise Reicin became a director |
| Feb 3, 2021 | ARCH Venture Partners X, LLC became a 10% owner |
| Feb 3, 2021 | ARCH Venture Partners X, L.P. became a 10% owner |
| Feb 3, 2021 | ARCH Venture Partners X Overage, L.P. became a 10% owner |
| Feb 3, 2021 | ARCH Venture Partners IX, LLC became a 10% owner |
| Feb 3, 2021 | ARCH Venture Partners IX Overage, L.P. became a 10% owner |
| Feb 3, 2021 | ARCH Venture Fund X, L.P. became a 10% owner |
| Feb 3, 2021 | ARCH Venture Fund X Overage, L.P. became a 10% owner |
| Feb 3, 2021 | ARCH Venture Fund IX, L.P. became a 10% owner |
| Feb 3, 2021 | ARCH Venture Fund IX Overage, L.P. became a 10% owner |
Not reported recently (30)
- Fmr LLC · Last reported as a 10% owner in an SEC filing dated Jan 10, 2025
- Douglas G. Cole · Last reported as a director in an SEC filing dated Jul 15, 2024
- Christian Hordo · Last reported as EVP, Chief Business Officer in an SEC filing dated Mar 8, 2024
- Noubar Afeyan · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Flagship Pioneering Inc. · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Flagship Pioneering Fund VII, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Flagship Pioneering Fund VII General Partner LLC · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Clinton Bybee · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- Kristina Burow · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Fund X Overage, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Partners X, LLC · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- Keith Crandell · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Partners IX, LLC · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Fund X, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Partners IX Overage, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- Steven Gillis · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Partners X Overage, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Fund IX, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Partners X, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Fund IX Overage, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- ARCH Venture Partners IX, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 12, 2024
- Flagship VentureLabs V LLC · Last reported as a 10% owner in an SEC filing dated Sep 15, 2023
- Flagship Pioneering Fund VI, L.P. · Last reported as a 10% owner in an SEC filing dated Sep 15, 2023
- Flagship VentureLabs V Manager LLC · Last reported as a 10% owner in an SEC filing dated Sep 15, 2023
- Flagship Pioneering Fund VI General Partner LLC · Last reported as a 10% owner in an SEC filing dated Sep 15, 2023
- Flagship Ventures Fund V General Partner LLC · Last reported as a 10% owner in an SEC filing dated Sep 15, 2023
- Flagship Ventures Fund V, L.P. · Last reported as a 10% owner in an SEC filing dated Sep 15, 2023
- Flagship V VentureLabs Rx Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Sep 15, 2023
- James J. MacDonald · Last reported as EVP & General Counsel in an SEC filing dated Jun 15, 2022
- Geoffrey von Maltzahn · Last reported as a director in an SEC filing dated Feb 18, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
SANA Proposed Insider Sales (Form 144)
Latest: 2025-02-18
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-02-18 | CHRISTIAN HORDO & KATHARINE HORDO | Officer | 75,000 | $237.0K | 2025-02-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-01-16 | CHRISTIAN HORDO & KATHARINE HORDO | Officer | 75,000 | $289.5K | 2025-01-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-12-16 | CHRISTIAN HORDO & KATHARINE HORDO JT TEN | Officer | 75,000 | $141.8K | 2024-12-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-11-26 | Hardy Nathan | Former CFO | 91,607 | $229.0K | 2024-11-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-11-25 | NATHAN HARDY | Former CFO | 25,933 | $65.0K | 2024-11-25 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-10-21 | NATHAN HARDY | Officer | 45,796 | $180.8K | 2024-10-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-09-25 | RICHARD MULLIGAN | Director | 150,000 | $613.5K | 2024-09-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-09-24 | RICHARD MULLIGAN | Director | 150,000 | $613.5K | 2024-09-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-12-15 | CHRISTIAN HORDO & KATHARINE HORDO JT TEN | Officer | 75,000 | $299.2K | 2023-12-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-06-07 | FLAGSHIP VENTURES FUND V, L.P. | Affiliate | 310,170 | $1.98M | 2023-06-07 | J.P. Morgan Securities LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
46 ETFs hold SANA
25 shown · $69.91M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $18.2M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.13% | $13.4M | $10.4B | 2026-10-20 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $10.3M | $75.1B | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $6.3M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.03% | $3.7M | $13.6B | 2026-10-20 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.03% | $3.3M | $11.0B | 2026-10-20 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $2.9M | — | 2026-09-30 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $2.5M | — | 2026-05-31 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.5M | — | 2026-09-30 |
| 10 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.03% | $1.4M | $4.2B | 2026-10-20 |
| 11 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.04% | $1.2M | — | 2026-07-31 |
| 12 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $605,873 | $97.4B | 2026-10-20 |
| 13 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.09% | $548,204 | — | 2026-10-21 |
| 14 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.03% | $544,076 | — | 2026-09-30 |
| 15 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.01% | $526,046 | $6.6B | 2026-10-20 |
| 16 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $494,186 | — | 2026-10-20 |
| 17 | OPTZ Optimize Strategy Index ETF | Nport | 0.17% | $489,357 | — | 2026-06-30 |
| 18 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $414,912 | — | 2026-05-31 |
| 19 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.78% | $363,005 | — | 2026-07-31 |
| 20 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $221,916 | $10.9B | 2026-10-20 |
| 21 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $201,813 | $3.8B | 2026-10-20 |
| 22 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $194,143 | — | 2026-10-21 |
| 23 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $119,225 | $20.6B | 2026-10-20 |
| 24 | TILT FlexShares Morningstar US Market Factor Tilt Index Fund | Nport | 0.00% | $70,225 | — | 2026-07-31 |
| 25 | ISCG iShares Morningstar Small-Cap Growth ETF | iShares (BlackRock) | 0.01% | $66,642 | $959.5M | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.76
TTM Revenue
—
TTM Net Income
$-211.82M
TTM Op. Cash Flow
$-132.24M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-63.63M | $-0.22 | $-32.79M |
| Q1 '26 | 2026-03-31 | — | $-47.21M | $-0.17 | $-37.38M |
| Q4 '25 | 2025-12-31 | — | $-58.83M | $-0.21 | $-32.64M |
| Q3 '25 | 2025-09-30 | — | $-42.15M | $-0.16 | $-29.43M |
| Q2 '25 | 2025-06-30 | — | $-93.80M | $-0.39 | $-33.10M |
| Q1 '25 | 2025-03-31 | — | $-49.39M | $-0.21 | $-48.66M |
| Q4 '24 | 2024-12-31 | — | $-49.07M | $-0.21 | $-47.16M |
| Q3 '24 | 2024-09-30 | — | $-59.92M | $-0.25 | $-51.82M |
| Q2 '24 | 2024-06-30 | — | $-50.29M | $-0.21 | $-58.54M |
| Q1 '24 | 2024-03-31 | — | $-107.47M | $-0.49 | $-65.63M |
| Q4 '23 | 2023-12-31 | — | $-88.12M | $-0.45 | $-51.96M |
| Q3 '23 | 2023-09-30 | — | $984.00K | — | $-63.55M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.24
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-137.0%
ROA
-49.1%
Div Yield
0.00%
FCF Yield
-20.16%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$655.98M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
38.73M
SI % of Float
21.03%
Days to Cover
8.96
Short Vol Ratio
47.0%
Free Float
184.14M
Float %
61.5%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14